Ab therapy of AML: native anti-CD33 Ab and drug conjugates

References

• Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–56
   PubMed Web of Science ®Google Scholar
• Stockerl-Goldstein KE, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. Hematopoietic Cell Transplantation, ED Thomas, KG Blume, SJ Forman. Blackwell Science, Oxford 1999; 823–34
   Google Scholar
• Sabbath KD, Ball ED, Larcom P, et al. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 1985; 75: 746–56
   PubMed Web of Science ®Google Scholar
• Andrews RG, Takahashi M, Segal GM, et al. The L4F3 antigen is expressed by unipotent colony-forming cells but not by their precursors. Blood 1986; 68: 1030–5
   PubMed Web of Science ®Google Scholar
• Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T-200 glycoprotein. J Exp Med 1980; 152: 842–52
   PubMed Web of Science ®Google Scholar
• Wahren B, Gadler F, Gahrton G, et al. NCA: a differentiation antigen of myelopoietic cells in human and hominoid monkeys. Ann NY Acad Sci 1983; 417: 344–58
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–61
   PubMed Web of Science ®Google Scholar
• Weisburg J, Roepe PD, Dzekunov S, Scheinberg DA. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J Biol Chem 1999; 274: 10877–88
   PubMed Web of Science ®Google Scholar
• Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478–90
   PubMed Web of Science ®Google Scholar
• Caron PC, Co MS, Bull MK, et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52: 6761–7
   PubMed Web of Science ®Google Scholar
• Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994; 83: 1760–8
   PubMed Web of Science ®Google Scholar
• Xu Y, Scheinberg DA. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin Cancer Res 1995; 1: 1179–87
   PubMed Web of Science ®Google Scholar
• Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 1998; 4: 1421–8
   PubMed Web of Science ®Google Scholar
• Feldman E, Kalaycio M, Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003; 17: 314–8
   PubMed Web of Science ®Google Scholar
• Vitale C, Romagnani C, Puccetti A, et al. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Science USA 2001; 98: 5764–9
   PubMed Web of Science ®Google Scholar
• Balaian L, Zhong RK, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies of AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol 2003; 5: 363–71
   Google Scholar
• Raza A, Jurcic JG, Roboz G , et al Increased dose intensity of SGN-33, a humanized monoclonal antibody targeting CD33, is active and well-tolerated in patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2006;108, (abstr 4568):221b–222b.
   Google Scholar
• Jurcic JG, Nimer SD, Scheinberg DA, et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98: 2651–6
   PubMed Web of Science ®Google Scholar
• Jurcic JG, DeBlasio T, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372–80
   PubMed Web of Science ®Google Scholar
• Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol 2001; 38: 37–45
   PubMed Web of Science ®Google Scholar
• Mulford DA, Maslak PG, Weiss MA, et al. Reducing standard postremission chemotherapy in acute promyelocytic leukemia with risk-adapted therapy. Blood 2003; 102(abstr 2287)619a–20a
   Google Scholar
• Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Exp Hematol 2005; 33: 199–211
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23: 4110–6
   PubMed Web of Science ®Google Scholar
• Caron PC, Lai L, Scheinberg DA. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (HuM195) (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1995; 1: 63–70
   PubMed Web of Science ®Google Scholar
• Calligiuri MA, Murray C, Soiffer RJ, et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 1991; 9: 2110–9
   Google Scholar
• Kossman SE, Scheinberg DA, Jurcic JG, et al. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin Cancer Res 1999; 5: 2748–55
   PubMed Web of Science ®Google Scholar
• Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198–201
   PubMed Web of Science ®Google Scholar
• Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93: 3678–84
   PubMed Web of Science ®Google Scholar
• Larson RA, Siievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104: 1442–52
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–6
   PubMed Web of Science ®Google Scholar
• Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578–82
   PubMed Web of Science ®Google Scholar
• Rajvanshi P, Schulman H, Sievers E, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 10–4
   PubMedGoogle Scholar
• Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia groups. Leukemia 2005; 19: 1768–73
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99: 4343–9
   PubMed Web of Science ®Google Scholar
• Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102: 4277–83
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Schiffer C, Stone R, et al. Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (‘Mylotarg’) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia. Blood 2002; 100(abstr 745)198a–9
   Google Scholar
• Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 2006; 108(abstract 13)8a
   Google Scholar
• Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine, and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003; 27: 893–7
   PubMed Web of Science ®Google Scholar
• Apostolidou E, Cortes J, Tsimberidou A, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003; 27: 887–91
   PubMed Web of Science ®Google Scholar
• Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 2002; 50: 497–500
   PubMed Web of Science ®Google Scholar
• Estey E, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamicin (‘Mylotarg’) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222–4
   PubMed Web of Science ®Google Scholar
• LoCoco F, Cimino G, Breccia M , et al Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;1995–9.
   Google Scholar
• Aribi A, Kantarjian HM, Estey EH, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007; 109: 1355–9
   PubMed Web of Science ®Google Scholar